Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis
Kai, A. C., Flohr, C. & Grattan, C. E., Jul 2014, In: Clinical and Experimental Dermatology. 39, 5, p. 651-652 2 p.
Research output: Contribution to journal › Letter › peer-review